NCT05031780Phase 2, phase 3Active not recruiting

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

Study sponsor: Agios Pharmaceuticals, Inc. · AGIO

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-10-30Actual
Enrollment · participants286Actual
Source updated2026-10-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2025. After: 30 Oct 2025.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview